Cardopan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardopan

Cardopan is a brand name for the active medication valsartan, which belongs to a class of drugs called Angiotensin II Receptor Blockers (ARBs). This medication is used to treat several cardiovascular conditions in adults and children (one year and older).


Quick Facts

  • Active Ingredient: Valsartan
  • Drug Class: Angiotensin II Receptor Blocker (ARB)
  • Primary Use: High blood pressure (hypertension), heart failure, and post-heart attack (myocardial infarction) treatment.

Mechanism of Action and Medical Uses

Valsartan works by interacting with the renin-angiotensin-aldosterone system (RAAS), a hormone system that regulates blood pressure and fluid balance. Specifically, it blocks the action of a hormone called Angiotensin II from binding to the AT1 receptor found on blood vessels and other tissues.

By blocking this action, valsartan causes the blood vessels to relax and widen, which helps to lower blood pressure and allows the heart to pump blood more efficiently. This mechanism is central to its therapeutic uses, which include:

  • Treating high blood pressure (hypertension).
  • Managing heart failure (a condition where the heart cannot pump enough blood).
  • Improving survival and reducing the risk of cardiovascular events after a recent heart attack in clinically stable patients with left ventricular dysfunction.

Valsartan is often used as a first-line treatment for hypertension and may also be used to slow the progression of kidney problems in individuals with Type 2 diabetes and high blood pressure.

What side effects are possible with Cardopan?

Possible Side Effects and Safety Information

Regulatory documents organize the safety profile of valsartan (Cardopan) by the frequency and type of adverse reactions observed. The most frequently documented side effects, classified as common in official sources, include headache, dizziness, fatigue, and viral infection. Certain populations, such as those treated for heart failure or post-myocardial infarction, may also commonly experience hypotension (low blood pressure) and elevated blood potassium levels (hyperkalemia).

Less frequent adverse reactions, categorized as uncommon, include vertigo, cough, and nausea. Very rare occurrences, based on postmarketing experience, include hepatitis and thrombocytopenia (a low platelet count). Other reactions, like angioedema (severe swelling), vasculitis, and hair loss (alopecia), have been reported but are listed as having a frequency not known.

Serious Adverse Reactions and Safety Constraints

The medicine carries a significant safety constraint regarding its use during pregnancy. It is classified with a Boxed Warning due to the risk of fetal toxicity, which can cause injury and death to the developing fetus, and is therefore contraindicated during the second and third trimesters. Clinically significant safety issues noted in regulatory texts include the potential for angioedema and the development of impaired renal function or acute renal failure, particularly in patients with severe heart conditions.

Furthermore, the use of valsartan is contraindicated in patients with severe hepatic impairment (severe liver problems). The regulatory profile specifies that symptomatic hypotension may rarely occur following the initiation of therapy in patients with volume or salt depletion.

Overdose and Emergency Response

Overdose and When to Seek Help

Documented Clinical Manifestations

Overdose of valsartan (Cardopan) is defined by officially documented effects on the cardiovascular system. The most likely clinical manifestation is significant hypotension, or markedly low blood pressure, according to regulatory sources. Changes in heart rate are also documented, most commonly presenting as tachycardia (fast heart rate), while bradycardia (slow heart rate) is listed as a possible presentation resulting from parasympathetic stimulation. These descriptions reflect the symptom profile written in government-authorized labeling.

Severe Outcomes and Mandated Action

Regulatory documents explicitly highlight severe, life-threatening outcomes reported in overdose cases. These include depressed level of consciousness, circulatory collapse, and shock. If symptomatic hypotension or any of these severe manifestations are observed, emergency medical care must be sought immediately. This action is mandated so that supportive treatment should be instituted without delay to manage the cardiovascular instability and prevent further severe outcomes.

Supportive Care and Limitations

The official regulatory profile confirms that treatment must focus on immediate supportive and symptomatic management. There is no specific antidote for valsartan documented in the official prescribing information. Furthermore, procedural notes specify that valsartan is not removed from the plasma by hemodialysis, which informs the approach to medical intervention in an acute overdose situation.

Therapeutic Uses of Cardopan

Cardopan (valsartan) is a foundational medicine used for the long-term management of chronic cardiovascular conditions, is applied across therapeutic domains where additional symptomatic support is needed, and is relevant for easing challenging symptoms.

Key Therapeutic Focus

Cardopan is commonly used to help with managing conditions marked by increased physiological stress, such as high blood pressure, heart failure, and post-heart attack care. It is applied in addressing symptoms that interfere with daily functioning, such as symptoms related to systemic imbalance (like shortness of breath and fluid retention). The support provided may contribute to improved comfort during periods of heightened symptoms, and may assist with maintaining functional stability.

The medication is considered relevant in conditions characterized by symptoms linked to organ-specific functional stress (for example, in patients with Type 2 diabetes and hypertension), and is used during phases when symptoms become more noticeable following an acute cardiac event.


Quick Fact: Relief for Circulatory Strain

The medicine may assist with managing the overall symptom burden and supports general well-being in contexts involving heightened systemic burden.

Eligibility and Restrictions for Use

Cardopan (valsartan) eligibility is strictly defined by regulatory authorities based on age, reproductive status, certain medical conditions, and specific drug combinations.

Populations with Absolute Restrictions (Contraindicated)

The medicine is formally contraindicated and must not be used in the following groups:

  • Pregnant women: Use is absolutely prohibited due to the risk of fetal injury and death.
  • Hypersensitivity: Patients with known allergy to valsartan or any component of the formulation.
  • Severe Hepatic Impairment: Patients diagnosed with severe liver failure, biliary cirrhosis, or cholestasis.
  • Dual RAS Blockade: Patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m^2) who are also taking medication containing aliskiren.

Eligibility and Use Limitations

Population Group Regulatory Status
Adults Approved for all official indications (hypertension, heart failure, post-heart attack treatment).
Children Approved for hypertension only in children aged mathbf6 years and older (some labels specify mathbf1 year and older).
Children <6 years Not recommended for hypertension (safety and efficacy are not established in this age range).
Severe Renal Impairment Not recommended for children of any age with a GFR <30 mL/min/1.73 m^2. Use in adults requires caution.
Breastfeeding Not recommended; a decision to discontinue nursing or the medication is advised.

Eligibility criteria for Cardopan are structured around these definitive restrictions and age limits established in official governmental drug labels.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Cardopan


Interaction scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Potassium-Sparing Diuretics, Potassium Supplements, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Angiotensin-Converting Enzyme (ACE) Inhibitors, OATP1B1 Inhibitors.
Specific interacting medicines (if explicitly listed) Aliskiren, Lithium.
Mechanistic basis of interactions (only if stated in label) Dual blockade of the Renin-Angiotensin System (RAS); Inhibition of the OATP1B1 uptake transporter.
Timing-based interaction rules (if applicable) None formally documented requiring separation of doses for co-administered medicines; valsartan may be administered with or without food.
Population-specific interaction notes (if applicable) Co-administration with Aliskiren is contraindicated in patients with diabetes mellitus or with renal impairment (GFR < 60 mL/min/1.73 m^2).
Interaction-related restrictions Co-administration with ACE Inhibitors is generally not recommended; Aliskiren co-administration is contraindicated in specific high-risk populations.

Interaction classifications (high-level)

Category Official Regulatory Classification/Basis
Interaction severity classification (as defined in official documents) Contraindicated; Generally Not Recommended; Clinically Significant.
Regulatory basis Based on official Prescribing Information (US FDA) and Summary of Product Characteristics (EMA).
Interaction-context constraints (as defined in official documents) Constraint with Aliskiren is conditional upon the presence of diabetes or renal impairment.

Resulting interaction structure

Official interaction statements:

  • Dual RAS blockade with Aliskiren is contraindicated in patients with diabetes or moderate-to-severe renal impairment due to increased risk of hyperkalemia and renal impairment.
  • Co-administration with Potassium-Sparing Diuretics or Potassium Supplements increases the documented risk of hyperkalemia (elevated serum potassium levels).
  • Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause the attenuation of the blood pressure-lowering effect and increase the risk of renal function decline, particularly in those with pre-existing impaired renal function.
  • Co-administration with Lithium is documented to increase serum lithium concentrations and the potential for toxicity.
  • Inhibitors of the OATP1B1 uptake transporter may result in increased systemic exposure to valsartan.
  • Alcohol may potentiate the risk of orthostatic hypotension.

Connection to the overall interaction profile (3 sentences):

Official regulatory documents define the interaction profile for valsartan through formally established contraindications and not-recommended combinations, primarily focused on dual blockade of the RAS. The structure highlights significant pharmacodynamic risks, such as hyperkalemia and renal function decline, with specific co-medications and substances. Additionally, the profile documents the potential for drug exposure modification with agents like Lithium and OATP1B1 inhibitors.

Mechanism of Action

Cardopan is a small molecule that functions as a selective antagonist of the P2 Y12 receptor. This receptor is highly expressed on the surface of circulating platelets.

The mechanism begins when Cardopan binds to the high-affinity P2 Y12 site, preventing the binding of the endogenous signaling molecule, Adenosine Diphosphate ( ADP). This P2 Y12 blockade inhibits the ADP-mediated activation of the GP IIb/ IIIa receptor complex, which is required for platelet aggregation.

The intracellular consequence of this antagonism is the disruption of the signaling cascade responsible for cytoskeletal rearrangement and the initiation of platelet-to-platelet adhesion. By modulating this key receptor pathway, Cardopan inhibits the cellular process of platelet aggregation and regulates the subsequent formation of platelet masses.

Dosage and Administration Information

How to Use Cardopan

Cardopan (valsartan) is administered strictly via the oral route and is supplied as film-coated tablets in various strengths, ranging from 40 mg up to 320 mg, in addition to an approved liquid oral suspension form. The frequency of use depends upon the cardiovascular condition being managed. For high blood pressure (hypertension), the medication is typically taken once daily, with starting doses usually set at 80 mg or 160 mg, and a maximum dose of 320 mg once daily.

For the management of heart failure and post-myocardial infarction care, the required frequency shifts to twice daily in divided doses. A key procedural rule is that administration is permitted with or without food. For chronic conditions, the full blood pressure-lowering effect is typically substantial within two weeks and maximal after four weeks of continuous use. For heart failure, the dose is gradually increased (titrated) at intervals of at least two weeks until the maximum tolerated dose is achieved.

High-level population adjustments include the guidance that no initial dosage change is generally required for older adults or those with mild to moderate kidney impairment. A specific constraint exists for the dosage form: the tablets and the liquid suspension are not interchangeable on a milligram-per-milligram basis, necessitating a dose re-evaluation if a patient switches formulations. The dose is generally limited to 80 mg for certain patients with non-cholestatic hepatic impairment.

Recent Clinical Evidence

Cardopan was studied for use in people with high blood pressure through large-scale, long-term Randomized Controlled Trials (RCTs). Research examined outcomes related to blood pressure measurements and the frequency of major events such as stroke and myocardial infarction. The interpretation of some comparative outcomes remains limited by early differences in blood pressure measurements between the groups being studied.

For chronic heart failure, Cardopan was evaluated in adult patients already receiving other standard medical treatments. Studies monitored all-cause mortality and a combined endpoint that tracked mortality and hospitalization. Findings describe patterns observed where the measurement of overall mortality was similar to the comparison group. However, the data related to the combined endpoint, which included hospitalization for heart failure, described a pattern of lower incidence in the Cardopan-treated group.

Following a heart attack, large-scale RCTs compared Cardopan monotherapy against an established standard-of-care monotherapy (an ACE inhibitor). Research describes that the measured all-cause mortality was similar when comparing the Cardopan monotherapy group to the ACE inhibitor monotherapy group. When researchers explored the use of the combination therapy (Cardopan plus an ACE inhibitor), the findings indicated no added therapeutic gain on survival.

The clinical evidence base includes major trials with follow-up durations that extended over multi-year periods. For certain specific health outcomes, long-term effects are not fully established beyond the observed duration of the clinical trials. A key finding that remains uncertain is the use of Cardopan with certain other standard-of-care medications in specific heart conditions, as the combination therapy was associated with either no added therapeutic gain or concerning patterns. Furthermore, while research has explored outcomes in special groups, including high-risk hypertensive adults and elderly patients, data for certain subgroups remain insufficient to draw broad conclusions.

Frequently Asked Questions (FAQ)

Common questions about Cardopan (FAQ)


Q: Why does Cardopan sometimes take a while to start working?

While the drug begins its initial blood pressure-lowering action within a few hours of the first dose, the full therapeutic benefit builds over time. Official regulatory information states that a substantial blood pressure reduction is typically present within two weeks, and the maximal effect is generally reached after four weeks of continuous use. This gradual timing is consistent with how the medication works to manage chronic conditions.


Q: How long does Cardopan stay in your system?

The active ingredient, valsartan, is designed to provide blood pressure control for a long duration. Pharmacokinetic studies show the drug has an average elimination half-life of about 6 hours, meaning it takes roughly that long for half the drug to be processed by the body. The drug's profile is consistent with a 24-hour dosing interval for many patients.


Q: Is it normal to feel more tired when first starting Cardopan?

Tiredness, or fatigue, is listed in official documents as a common side effect reported in clinical trials. It is described as a non-serious adverse reaction. If this feeling is severe or concerning, the official patient information advises contacting a healthcare professional.


Q: What happens if I stop taking Cardopan suddenly?

Cardopan is approved for the long-term management of chronic conditions such as high blood pressure and heart failure. Stopping any treatment should be done only under the direction of a healthcare professional to ensure proper management of chronic conditions, as noted in general medical principles.


Q: Does Cardopan affect blood sugar levels?

The medication is sometimes used to help slow the progression of kidney issues in individuals with Type 2 diabetes and high blood pressure. While its main purpose is blood pressure control, some clinical studies noted in medical literature indicate a potential for slight improvements in glucose and related vascular health metrics in this patient population.


Q: Can Cardopan cause dizziness or lightheadedness?

Yes, dizziness is a very common side effect reported in clinical trials. Official warnings also note that lightheadedness, particularly when standing up quickly (known as orthostatic hypotension), may occur, especially in patients who are volume-depleted or have heart failure.


Q: What is the intended duration of treatment with Cardopan?

Cardopan is officially indicated for the management of chronic, long-term conditions, including high blood pressure and heart failure. For these indications, the treatment plan is typically intended to be ongoing to maintain the therapeutic effect and manage the underlying disease.


Q: Is Cardopan the only option for the condition it treats?

Cardopan is the brand name for the active ingredient valsartan, which belongs to a class of medications called Angiotensin II Receptor Blockers (ARBs). This drug class is one of several types of medications officially approved and used for treating high blood pressure and related cardiovascular issues.


Q: Can Cardopan affect your sleep?

Difficulty sleeping, or insomnia, has been listed in some post-marketing reports as an adverse event. However, official regulatory documents state the frequency of this occurrence is not known.


Q: Is it okay to have coffee or tea while taking Cardopan?

Official regulatory documents do not list a specific interaction with common beverages like coffee or tea. The medication is permitted to be taken with or without food, giving flexibility in daily routines.


Q: Is Cardopan generally appropriate for older adults (seniors)?

The drug was included in studies of older adults, and regulatory documents state that no initial dosage adjustment is typically required for this population when treating high blood pressure. However, studies show that older adults may have a higher systemic exposure to the drug.


Q: Is Cardopan used for treating anxiety or just physical conditions?

The official indications for Cardopan are strictly for treating physical conditions: high blood pressure, heart failure, and post-heart attack care. Anxiety has been reported as a psychiatric adverse event in post-marketing experience, but it is not an approved use for this medication.


Q: Are there any long-term effects of taking Cardopan for many years?

Clinical trials for the drug extended over multi-year periods, showing the therapeutic effect was maintained during that time. Research documentation notes that for certain specific long-term health outcomes, the effects are not fully established beyond the observed duration of the clinical trials.


Q: Does Cardopan need to be taken at the same time every day?

Cardopan is prescribed for either once-daily or twice-daily use, and its blood pressure-lowering effects last for 24 hours. A consistent daily schedule is a general principle for maintaining the intended therapeutic coverage of continuous medications.


Q: Can Cardopan be cut in half, or should it always be swallowed whole?

This depends on the specific dosage strength of the tablet. Official drug labeling specifies that the 40 mg tablet dosage form is manufactured as a scored tablet, meaning it has an indent line to aid in splitting. Other tablet strengths are typically not scored, and patients are advised to follow their product's specific instructions regarding splitting.


Q: Is Cardopan addictive or habit-forming?

Cardopan (valsartan) is classified by the U.S. government as not a controlled substance. It is not considered to be addictive or habit-forming.


Q: Are there any specific supplements that should be avoided while on Cardopan?

Official labeling advises caution with supplements containing potassium. Co-administration with potassium supplements may increase the risk of hyperkalemia, which is an elevated level of potassium in the blood. This is a clinically significant interaction documented in regulatory materials.


Q: Can Cardopan be taken with vitamins?

Official regulatory documents do not list general vitamins as documented interacting substances. However, it is advised to review any co-administered products, including vitamin supplements, with a healthcare professional.


Q: Is Cardopan a once-a-day medicine?

The required frequency depends on the condition being treated. For high blood pressure, it is typically taken once daily. For heart failure and post-heart attack treatment, however, the frequency is twice daily, according to official dosage information.


Q: Can I drive or operate machinery after taking Cardopan?

Patients are advised to use caution and avoid driving or operating complex machinery until they are aware of how the medicine affects them, due to the risk of side effects like dizziness or lightheadedness, as noted in patient information.


Q: What does it mean that Cardopan 'blocks' a certain receptor?

Cardopan belongs to a class of drugs called Angiotensin II Receptor Blockers (ARBs). It works by physically blocking the AT1 receptor on blood vessels and other tissues. This prevents the hormone Angiotensin II from binding to the receptor, which helps the blood vessels relax and widen to lower blood pressure.


Q: Is a slight headache a common side effect when starting Cardopan?

Yes, headache is listed in official documentation as a very common side effect reported in clinical trials. This is a known initial effect and is consistent with the drug’s safety profile.


Q: Is it normal for my pulse to feel slower when I'm on Cardopan?

Cardopan's primary mechanism of action targets the regulation of blood pressure, not the heart rate. Clinical studies have shown that the treatment resulted in essentially no measurable change in heart rate for patients, suggesting a noticeably slower pulse would not be a typical effect of the medication itself.


Q: What are the signs that Cardopan might not be working for someone?

The primary indicator of the drug’s intended effect is the measured decrease in blood pressure or improvement in symptoms related to heart failure. Regulatory guidelines recommend monitoring blood pressure to assess the response. If blood pressure remains high or symptoms do not improve after the standard period (e.g., 2 to 4 weeks), this may suggest the need for a dose adjustment or re-evaluation.


Q: What should be checked on the label before using Cardopan?

The label contains critical warnings and contraindications from regulatory authorities. These include the Boxed Warning regarding the risk of fetal injury during pregnancy, the prohibition for use in patients with severe liver impairment, and restrictions against co-administration with aliskiren in certain diabetic or kidney impairment patients.


Q: Why might a doctor switch me from a different medicine to Cardopan?

Cardopan (valsartan) belongs to the ARB class of drugs. Medical literature suggests that ARBs are often an alternative choice when a patient experiences common side effects, such as a persistent dry cough, while taking a different class of blood pressure medicine called an ACE inhibitor.

How should Cardopan be stored and disposed of?

Storage Requirements for Cardopan (Valsartan)

Item Official Storage Condition
Tablets Store at Controlled Room Temperature: 68 F to 77 F (20 C to 25 C), with brief excursions permitted [1].
Protection Keep the tablets in a tightly closed container away from heat, moisture, direct light, and do not freeze [1].
Compounded Suspension (Shelf-Life) Stable for up to 75 days when refrigerated (35 F–46 F), or up to 30 days at room temperature (below 86 F) [1].
Handling The liquid suspension must be shaken well for at least 10 seconds before dispensing [1].
Child Safety The medication must be kept out of the reach of children [1].

Disposal Instructions

Official regulatory guidelines require that any unused or outdated Cardopan product must be disposed of according to local regulations [1]. Consumers are instructed to ask their healthcare professional for guidance on discarding medicine no longer needed [1].


[1] FDA Prescribing Information for Diovan (valsartan)

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardopan found in:

A-Z Index: